ENTO logo
Entero Therapeutics, Inc.(ENTO)
Closing price · checked 4:31 PM ETAbout this dataData status
$2.85▼-0.15 (-5.00%)
Extended:$3.10+0.25 (+8.77%)· 4:31 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Entero Therapeutics, Inc. focuses on developing innovative therapies for gastrointestinal disorders, particularly leveraging its proprietary drug delivery platform. The company is positioned to address unmet medical needs in the treatment of conditions such as short bowel syndrome and inflammatory bowel disease, primarily in the U.S. and Europe.

HealthcareBiotechnologylow - Entero's high fixed costs associated with R&D and clinical trials limit its operating leverage, particularly in the absence of significant revenue.

Business Overview

01Therapeutic sales - 100%

Entero generates revenue through the commercialization of its proprietary drug therapies, which are designed to enhance drug absorption in the gastrointestinal tract. The company benefits from a unique delivery mechanism that allows for improved bioavailability of medications, providing a competitive edge in the biotech space.

What Moves the Stock

FDA approval of new drug candidates

Clinical trial results impacting market perception

Partnerships or collaborations with larger pharmaceutical companies

Market adoption rates of existing therapies

Watch on Earnings
Clinical trial progress updatesRegulatory approval timelinesMarket penetration of existing products

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption in drug delivery methods

Emergence of alternative therapies that could replace Entero's offerings

Increased competition from established pharmaceutical companies

Liquidity risk due to negative cash flows and reliance on external funding

Potential for increased operational costs without corresponding revenue growth

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The demand for biotechnology products is relatively inelastic, as they address critical health needs regardless of economic conditions.

Interest Rates

Moderate - Rising interest rates could increase the cost of capital for R&D financing, impacting the company's ability to fund clinical trials and operational expenses.

Credit

minimal - Entero has a low debt-to-equity ratio, indicating limited reliance on external financing.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

high - The stock exhibits high volatility due to the binary nature of clinical trial outcomes and regulatory approvals.

Key Metrics to Watch
FDA approval timelines for new drug candidates
Clinical trial enrollment rates
Market share of existing therapies
R&D expenditure as a percentage of revenue
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.